Phenobarbital, Midazolam Pharmacokinetics, Effectiveness, and Drug-Drug Interaction in Asphyxiated Neonates Undergoing Therapeutic Hypothermia
Favié, Laurent M.A.; Groenendaal, Floris; Van Den Broek, Marcel P.H.; Rademaker, Carin M.A.; De Haan, Timo R.; Van Straaten, Henrica L.M.; Dijk, Peter H.; Van Heijst, Arno; Simons, Sinno H.P.; Dijkman, Koen P.; Rijken, Monique; Zonnenberg, Inge A.; Cools, Filip; Zecic, Alexandra; Van Der Lee, Johanna H.; Nuytemans, Debbie H.G.M.; Van Bel, Frank; Egberts, Toine C.G.; Huitema, Alwin D.R.
(2019) Neonatology, volume 116, issue 2, pp. 154 - 162
(Article)
Abstract
Background: Phenobarbital and midazolam are commonly used drugs in (near-)term neonates treated with therapeutic hypothermia for hypoxic-ischaemic encephalopathy, for sedation, and/or as anti-epileptic drug. Phenobarbital is an inducer of cytochrome P450 (CYP) 3A, while midazolam is a CYP3A substrate. Therefore, co-treatment with phenobarbital might impact midazolam clearance. Objectives: To assess
... read more
pharmacokinetics and clinical anti-epileptic effectiveness of phenobarbital and midazolam in asphyxiated neonates and to develop dosing guidelines. Methods: Data were collected in the prospective multicentre PharmaCool study. In the present study, neonates treated with therapeutic hypothermia and receiving midazolam and/or phenobarbital were included. Plasma concentrations of phenobarbital and midazolam including its metabolites were determined in blood samples drawn on days 2-5 after birth. Pharmacokinetic analyses were performed using non-linear mixed effects modelling; clinical effectiveness was defined as no use of additional anti-epileptic drugs. Results: Data were available from 113 (phenobarbital) and 118 (midazolam) neonates; 68 were treated with both medications. Only clearance of 1-hydroxy midazolam was influenced by hypothermia. Phenobarbital co-administration increased midazolam clearance by a factor 2.3 (95% CI 1.9-2.9, p < 0.05). Anticonvulsant effectiveness was 65.5% for phenobarbital and 37.1% for add-on midazolam. Conclusions: Therapeutic hypothermia does not influence clearance of phenobarbital or midazolam in (near-)term neonates with hypoxic-ischaemic encephalopathy. A phenobarbital dose of 30 mg/kg is advised to reach therapeutic concentrations. Phenobarbital co-administration significantly increased midazolam clearance. Should phenobarbital be substituted by non-CYP3A inducers as first-line anticonvulsant, a 50% lower midazolam maintenance dose might be appropriate to avoid excessive exposure during the first days after birth.
show less
Download/Full Text
Keywords: Hypoxic-ischaemic encephalopathy, Midazolam, Neonates, Pharmacokinetics, Phenobarbital, Pediatrics, Perinatology, and Child Health, Developmental Biology, Journal Article
ISSN: 1661-7800
Publisher: S. Karger AG
Note: Publisher Copyright: © 2019 The Author(s) Published by S. Karger AG, Basel.
(Peer reviewed)